Financial history
| 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cochlear Implant System Sales (units) | 23,087 | 24,661 | 21,023 | 18,553 | 18,228 | 15,947 | 12,901 | 10,802 | 9,306 | 9,328 |
| Income Statement ($m) | ||||||||||
| Total Revenue | 779.0 | 809.6 | 734.8 | 694.7 | 601.7 | 559.4 | 452.3 | 349.0 | 282.8 | 306.1 |
| R&D expenses | 119.3 | 108.9 | 94.9 | 96.7 | 80.0 | 65.9 | 56.7 | 44.6 | 44.5 | 37.0 |
| Profit after Income Tax * | 56.8 | 180.1 | 155.2 | 130.5 | 115.2 | 100.1 | 80.0 | 59.6 | 36.8 | 58.2 |
| EBITDA * | 239.4 | 270.1 | 243.6 | 205.5 | 193.3 | 170.9 | 130.2 | 96.8 | 54.9 | 87.9 |
| EBIT * | 215.3 | 242.7 | 220.5 | 183.3 | 167.3 | 150.2 | 111.5 | 82.5 | 45.5 | 80.1 |
| Profit after Income Tax * | 158.1 | 180.1 | 155.2 | 130.5 | 115.2 | 100.1 | 80.0 | 59.6 | 36.8 | 58.2 |
| Balance Sheet ($m) | ||||||||||
| Total Assets | 702.5 | 741.0 | 751.7 | 679.4 | 607.9 | 586.3 | 545.9 | 502.7 | 264.5 | 230.6 |
| Total Liabilities | 317.7 | 237.8 | 313.4 | 315.1 | 288.6 | 325.5 | 336.1 | 348.0 | 119.0 | 110.9 |
| Statistics | ||||||||||
| Basic EPS (cents) | 100.0 | 318.2 | 275.7 | 233.7 | 208.1 | 182.9 | 146.8 | 110.1 | 68.2 | 110.0 |
| DPS (cents) | 245 | 225 | 200 | 175 | 150 | 125 | 100 | 80 | 79 | 77 |
| Other Data | ||||||||||
| Closing Share Price ($) | 65.84 | 72.00 | 74.32 | 57.70 | 43.65 | 61.00 | 54.63 | 39.20 | 22.72 | 32.30 |
| Market Capitalisation as at 30 June ($m) | 3,744 | 4,081 | 4,198 | 3,230 | 2,423 | 3,341 | 2,985 | 2,123 | 1,231 | 1,714 |
| Number of Employees | 2,390 | 2,319 | 2,006 | 1,888 | 1,789 | 1,655 | 1,100 | 982 | 816 | 814 |
Financial amounts for 2005 to 2012 are in accordance with AIFRS. Financial amounts for 2003 and 2004 are in accordance with previous GAAP.
* Excludes product recall expenses of $138.8 million before tax and $101.3 million after tax in 2012
Given the significance of the product recall the directors believe the presentation of non-IFRS financial measures is useful for the users of this document as they reflect the underlying financial performance of the business. The amounts excluding recall costs have been calculated using the IFRS financial measures adjusted for the costs of the product recall.